Biotech startups that raised Series D or later in Europe
Updated 16 Nov 2026
Not sure about the data?
Download a free 10-row sample first. No account, no payment.
| Company | City | Last round | Amount | Date |
|---|---|---|---|---|
| bit.bio | Cambridge | Series D | $25.0M | 2026-11-04 |
| CellCentric | Cambridge | Series D | $220.0M | 2026-05-06 |
| MedTrace Pharma | Lyngby | Series F | $11.1M | 2025-05-12 |
| Alentis Therapeutics | Allschwil | Series D | $181.4M | 2024-11-12 |
| CatalYm | Planegg | Series D | $150.0M | 2024-07-16 |
| Phagenesis | Manchester | Series D | $42.0M | 2024-03-04 |
| Lunaphore | Lausanne | Series D | $32.7M | 2023-03-23 |
| iThera Medical | Munich | Series D | $13.8M | 2022-12-21 |
8 rows of the CSV in 5 of its 18 columns.
- The 42 biotech startups in Europe whose last round is Series D or later have raised $3.1B in total.
- 5 of them closed their most recent round in the last 12 months, $528.7M combined.
- The largest of those rounds is CellCentric's $220.0M Series D, dated May 2026.
- The most recent is bit.bio's $25.0M Series D on 4 November 2026.
- Bayern Kapital is an investor in 5 of them, more than any other fund.
- Health care is the most common other sector, with 41 companies (98%).
- 0% were founded in 2020 or later; the median founding year is 2007.
- The most common team size is 11 to 50 employees (72% of companies with a recorded size).
Source: FundingWatcher. Data as of 16 November 2026. "Last 12 months" is the 365 days to that date.
Newest rounds
10 of 42| Company | What they do | Sector | Location | Last round | Amount | Date | Total raised | Investors | Employees | Founded |
|---|---|---|---|---|---|---|---|---|---|---|
| bit.bio | Bit.bio provides engineered human cell products and platform services for biomedical research and drug discovery. | Biotech | Cambridge, United Kingdom | Series D | $25.0M | 2026-11-04 | $250.0M | Metaplanet, Foresite Capital | 101 to 250 | 2016 |
| CellCentric | CellCentric develops small molecule therapies for treating cancer and multiple myeloma. | Biotech | Cambridge, United Kingdom | Series D | $220.0M | 2026-05-06 | $475.7M | Innovate UK, 5Y Capital, RA Capital Management +2 | 11 to 50 | 2003 |
| MedTrace Pharma | MedTrace Pharma helps doctors diagnose critically ill patients faster and more accurately. | Biotech | Lyngby, Denmark | Series F | $11.1M | 2025-05-12 | $63.4M | European Innovation Council, Vaekstfonden, ATP +1 | 11 to 50 | 2015 |
| Alentis Therapeutics | Alentis Therapeutics develops novel therapeutics for advanced liver disease and cancer. | Biotech | Allschwil, Switzerland | Series D | $181.4M | 2024-11-12 | Bpifrance, HTGF (High-Tech Gruenderfonds), RA Capital Management +2 | 51 to 100 | 2019 | |
| CatalYm | CatalYm develops immunotherapies to treat cancer. | Biotech | Planegg, Germany | Series D | $150.0M | 2024-07-16 | $260.9M | Bayern Kapital, Forbion Capital Partners, Novartis Venture Fund +1 | 11 to 50 | 2016 |
| Phagenesis | Phagenesis develops a device that treats dysphagia, a condition that makes swallowing food unsafe. | Biotech | Manchester, United Kingdom | Series D | $42.0M | 2024-03-04 | $71.4M | MedTech Innovator, EQT Life Sciences, Northern Gritstone +2 | 11 to 50 | 2007 |
| Lunaphore | Lunaphore is a life sciences company that creates technologies enabling spatial biology in all laboratories. | Biotech | Lausanne, Switzerland | Series D | $32.7M | 2023-03-23 | Venture Kick, VentureOut, redalpine | 11 to 50 | 2014 | |
| iThera Medical | iThera Medical develops proprietary MSOT imaging technology for preclinical and clinical applications. | Biotech | Munich, Germany | Series D | $13.8M | 2022-12-21 | $42.3M | European Innovation Council, Bayern Kapital, German Federal Ministry of Research, Technology and Space +1 | 11 to 50 | 2010 |
| Biosystems International | Biosystems International develops blood-based diagnostics for cancer and chronic diseases. | Biotech | Debrecen, Hungary | Series D | $2.8M | 2020-10-29 | Societe Generale Asset Management, Amundi Private Equity Funds | 11 to 50 | 2004 | |
| Phenex Pharmaceuticals | Phenex Pharmaceuticals discovers and develops novel pharmaceutical drugs. | Biotech | Heidelberg, Germany | Series D | $6.5M | 2012-10-31 | KfW, Creathor Ventures, LBBW VC +2 | 11 to 50 | 2002 |
Table 1. Biotech startups that raised Series D or later in Europe: the 10 newest rounds whose row carries a description, a city, a named fund and an amount. Source: FundingWatcher. Data as of 16 November 2026. Base: 42.
Largest rounds
Last 12 months| # | Company | What they do | Sector | Location | Last round | Amount | Date | Total raised | Investors | Employees | Founded |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | CellCentric | CellCentric develops small molecule therapies for treating cancer and multiple myeloma. | Biotech | Cambridge, United Kingdom | Series D | $220.0M | 2026-05-06 | $475.7M | Innovate UK, 5Y Capital, RA Capital Management +2 | 11 to 50 | 2003 |
| 2 | bit.bio | Bit.bio provides engineered human cell products and platform services for biomedical research and drug discovery. | Biotech | Cambridge, United Kingdom | Series D | $25.0M | 2026-11-04 | $250.0M | Metaplanet, Foresite Capital | 101 to 250 | 2016 |
Table 2. Biotech startups that raised Series D or later in Europe: the 2 largest rounds of the last 12 months. Source: FundingWatcher. Data as of 16 November 2026.
Most active investors
By companies backed| # | Investor | Type | Location | Companies | Share | Funded, 12 months | Latest |
|---|---|---|---|---|---|---|---|
| 1 | Bayern Kapital | Venture capital firm | Landshut, Germany | 5 | 12% | ||
| 2 | KfW | Government investment office | Frankfurt, Germany | 3 | 7% | ||
| 3 | RA Capital Management | Startup incubator | Boston, United States | 2 | 5% | 1 | CellCentric |
| 4 | European Innovation Council | Startup accelerator | Brussels, Belgium | 2 | 5% | ||
| 5 | HTGF (High-Tech Gruenderfonds) | Venture capital firm | Bonn, Germany | 2 | 5% | ||
| 6 | Signet Healthcare Partners | Venture capital firm | New York, United States | 2 | 5% | ||
| 7 | Novartis Venture Fund | Corporate venture arm | Basel, Switzerland | 2 | 5% | ||
| 8 | Forbion Capital Partners | Private equity firm | Naarden, The Netherlands | 2 | 5% | ||
| 9 | EQT Life Sciences | Private equity firm | Amsterdam, The Netherlands | 2 | 5% | ||
| 10 | Venture Kick | Startup incubator | Schlieren, Switzerland | 2 | 5% | ||
| 11 | MIG Capital | Venture capital firm | Munich, Germany | 2 | 5% | ||
| 12 | Foresite Capital | Private equity firm | San Francisco, United States | 1 | 2% | 1 | bit.bio |
| 13 | Metaplanet | Venture capital firm | Tallinn, Estonia | 1 | 2% | 1 | bit.bio |
| 14 | 5Y Capital | Venture capital firm | Xuhui, China | 1 | 2% | 1 | CellCentric |
| 15 | Pfizer | Corporate venture arm | New York, United States | 1 | 2% | 1 | CellCentric |
Table 3. Biotech startups that raised Series D or later in Europe: the funds recorded as investors in the most companies. Latest: companies they back that raised in the last 12 months. Source: FundingWatcher. Data as of 16 November 2026.
Sectors
| Sectors | Companies | Share | Total raised |
|---|---|---|---|
| Health care | 41 | 98% | $3.1B |
| Software | 3 | 7% | $32.3M |
| Energy | 1 | 2% |
Table 4. Biotech startups that raised Series D or later in Europe by sector. Source: FundingWatcher. Data as of 16 November 2026.
Funding stage
| Funding stage | Companies | Share | Median last round |
|---|---|---|---|
| Series D+ | 42 | 100% | $23.7M |
Table 5. Biotech startups that raised Series D or later in Europe by stage of the most recent round. Source: FundingWatcher. Data as of 16 November 2026.
Countries
| Countries | Companies | Share |
|---|---|---|
| United Kingdom | 12 | 29% |
| Germany | 9 | 21% |
| Switzerland | 6 | 14% |
| France | 6 | 14% |
| Belgium | 3 | 7% |
| Austria | 1 | 2% |
| Denmark | 1 | 2% |
| Ireland | 1 | 2% |
| Hungary | 1 | 2% |
| Spain | 1 | 2% |
| Sweden | 1 | 2% |
Table 6. Biotech startups that raised Series D or later in Europe by headquarters country. Source: FundingWatcher. Data as of 16 November 2026.
Cities
| Cities | Companies | Share |
|---|---|---|
| Cambridge | 5 | 12% |
| Paris | 3 | 7% |
| Manchester | 3 | 7% |
| Munich | 2 | 5% |
| Basel | 1 | 2% |
| Innsbruck | 1 | 2% |
| Lyngby | 1 | 2% |
| Allschwil | 1 | 2% |
| Antwerp | 1 | 2% |
| Planegg | 1 | 2% |
| Lausanne | 1 | 2% |
| Galway | 1 | 2% |
Table 7. Biotech startups that raised Series D or later in Europe by headquarters city. Source: FundingWatcher. Data as of 16 November 2026.
Rounds by month
| Rounds by month | Companies | Share | Raised |
|---|---|---|---|
| November 2026 | 1 | 20% | $25.0M |
| October 2026 | 1 | 20% | $134.7M |
| June 2026 | 1 | 20% | $34.0M |
| May 2026 | 1 | 20% | $220.0M |
| November 2025 | 1 | 20% | $115.0M |
Table 8. Biotech startups that raised Series D or later in Europe: most recent round by month, last 12 months. Source: FundingWatcher. Data as of 16 November 2026.
Most recent round by year
| Most recent round by year | Companies | Share | Raised |
|---|---|---|---|
| 2026 | 4 | 10% | $413.7M |
| 2025 | 3 | 7% | $126.1M |
| 2024 | 6 | 14% | $562.1M |
| 2023 | 2 | 5% | $64.9M |
| 2022 | 3 | 7% | $57.1M |
| 2021 | 1 | 2% | $88.0M |
Table 9. Biotech startups that raised Series D or later in Europe by year of the most recent round. Source: FundingWatcher. Data as of 16 November 2026.
Founding year
| Founding year | Companies | Share |
|---|---|---|
| 2015 to 2019 | 7 | 17% |
| 2010 to 2014 | 7 | 17% |
| Before 2010 | 28 | 67% |
Table 10. Biotech startups that raised Series D or later in Europe by founding year. Source: FundingWatcher. Data as of 16 November 2026.
Team size
| Team size | Companies | Share |
|---|---|---|
| 1 to 10 | 1 | 3% |
| 11 to 50 | 28 | 72% |
| 51 to 100 | 6 | 15% |
| 101 to 250 | 3 | 8% |
| 251 to 500 | 1 | 3% |
Table 11. Biotech startups that raised Series D or later in Europe by headcount. Source: FundingWatcher. Data as of 16 November 2026.
Method
- A company is on this list when Biotech is one of its sectors and its most recent funding round is Series D or later and its headquarters is in Europe. On 16 November 2026 that is 42 companies.
- Stage, round, amount and date are those of the company's most recent funding round. Amounts are in US dollars as the source records them.
- The table prints the 10 newest rounds whose row is complete: a one-sentence description, a city, a named fund and an amount. The CSV carries all 42 rows: 5 have no round amount, 0 no city and 17 no website. The CSV carries domain, website, LinkedIn and the cached description sentence where present.
Sources, fields and exclusions of both files: Method.
Questions
- How many biotech startups in Europe whose last round is Series D or later are on the list?
- 42, in the file dated 16 November 2026. 5 of them closed their most recent round in the last 12 months.
- What does the CSV contain?
- One row per company, 18 columns: name, domain, website, linkedin, description, founded, employees, city, region, country, sectors, funding_stage, last_round, last_round_date, last_round_usd, total_raised_usd, rounds, investors.
- How much does the list cost?
- $29 one-time for all 42 rows, no account. Every investor and every startup, two files, cost $99. With founder contacts, up to 2 founders or CEOs per company compiled to order and mailed within 24 hours, $199.
- What arrives after payment?
- At once: the CSV download link, on the page after payment and by mail.
- Can I see rows before buying?
- The 3 rows under the buy button are rows of the CSV with every column. The form below it mails 10 rows.
- How current is the data?
- The file is dated 16 November 2026. The download link serves the current file each time it is opened.
Not sure about the data?
Download a free 10-row sample first. No account, no payment.